☆ 4.8 Review

Primary brain tumours in adults

LANCET (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics

Kee Kiat Yeo et al.

Summary: This study found that a subset of pediatric gliomas is driven by IDH1/2 mutations, with a higher rate among adolescents. The majority of patients underwent upfront observant management without adjuvant therapy. The findings suggest that the natural history of pediatric IDH1/2-mutant glioma may be similar to that of adults.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Antonio Omuro et al.

Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma

Shawn L. Hervey-Jumper et al.

Summary: In patients with diffuse low-grade glioma, the extent of surgical tumor resection has a controversial role in prognosis, but a randomized clinical trial is not feasible to determine different levels of resection.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study

Michael Hauptmann et al.

Summary: The European EPI-CT study aims to assess the risk of brain cancer from CT examinations in children and young adults. Using data from nine European countries, the study found a significant dose-response relationship between CT-related radiation exposure and brain cancer.

LANCET ONCOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Autonomous rhythmic activity in glioma networks drives brain tumour growth

David Hausmann et al.

Summary: This study reveals the impact of network architecture and communication strategies on the biology of glioblastoma, a type of brain tumor. The findings demonstrate the crucial role of periodic Ca2+ activity in the network, and show that targeting this activity can significantly weaken global network communication and reduce tumor cell viability. The study highlights the vulnerability of glioblastoma networks and suggests the potential for developing novel therapies.

NATURE (2023)

Add to Collection

Article Oncology

EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

David Capper et al.

Summary: The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied.

NEURO-ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?

Matthias Preusser et al.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial

Linda M. Liau et al.

Summary: The study shows that adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax L) to standard of care can extend the survival of patients with glioblastoma.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial

Andrew B. Lassman et al.

Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Christina I. Tsien et al.

Summary: This study evaluated whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS) compared to BEV alone in recurrent glioblastoma (GBM). The results showed that the combination of re-RT and BEV significantly improved PFS, but had no difference in OS.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Ingo K. Mellinghoff et al.

Summary: In a pilot perioperative randomized clinical trial, the dual IDH1/IDH2 inhibitor vorasidenib was found to have better brain permeability and target engagement than ivosidenib in patients with IDH1-mutant glioma. Both agents showed significant reduction in tumor 2-HG concentrations, with vorasidenib demonstrating more consistent suppression. Exploratory analyses revealed additional positive effects of 2-HG reduction. Vorasidenib was selected for further testing in phase 3 trials. This study was funded by Agios Pharmaceuticals, Inc. and Servier Pharmaceuticals LLC.

NATURE MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Glioma

Ingo K. Mellinghoff et al.

Summary: In a phase 3 trial, vorasidenib showed significant improvement in progression-free survival and delay in the time to the next intervention for patients with grade 2 IDH-mutant glioma.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Patrick Y. Wen et al.

Summary: The study evaluated the efficacy and safety of dabrafenib plus trametinib in patients with high-grade glioma and low-grade glioma who had BRAF(V600E) mutation. The results showed that dabrafenib plus trametinib demonstrated meaningful activity in the treatment of recurrent or refractory high-grade glioma and low-grade glioma with BRAF(V600E) mutation, and had a safety profile consistent with other indications.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

Jasmin Jo et al.

Summary: For IDH-mutant gliomas, there is still confusion on how to conduct long-term surveillance and imaging follow-up. Existing guidelines do not clearly specify individualized imaging guidelines based on treatment and tumor recurrence. In this study, we review current knowledge and propose recommended MRI surveillance intervals, as well as summarize situations where additional imaging studies may be advisable outside of the specified intervals.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Clinical Neurology

Tumor Syndromes Neurosurgical Evaluation and Management

Aravinda Ganapathy et al.

Summary: Identifying whether a CNS malignancy is related to a genetic syndrome is crucial for guiding screening modalities, timing, treatment options, and familial counseling. It is important for pediatric neurosurgeons to be able to recognize when a syndrome may be underlying a patient's disease. The care of patients with CNS tumor syndromes must involve a multidisciplinary approach.

NEUROSURGERY CLINICS OF NORTH AMERICA (2022)

Add to Collection

Article Oncology

Environmental and sex-specific molecular signatures of glioma causation

Elizabeth B. Claus et al.

Summary: This study finds that cancer-causing mutations in gliomas primarily originate from endogenous factors rather than exogenous factors, with differences in mutation locations in the phosphoinositide 3-kinase (PI3K) pathway between males and females. Additionally, a rare environmental risk factor is suggested for some cases of glioma, particularly in males.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Cellular Telephone Use and the Risk of Brain Tumors: Update of the UK Million Women Study

Joachim Schuz et al.

Summary: The ongoing debate regarding cellular telephone use and brain tumor risk was addressed by a large-scale prospective study. The findings support the evidence that usual cellular telephone use does not increase the incidence of brain tumors.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Oncology

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Michael Lim et al.

Summary: The study evaluated the addition of the immune checkpoint inhibitor nivolumab (NIVO) to radiotherapy (RT) + temozolomide (TMZ) in newly diagnosed glioblastoma patients and found that it did not improve survival in these patients.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States

J. Bryan Iorgulescu et al.

Summary: The study investigated the completeness and validity of molecular biomarkers for brain tumor patients in 2018, and described the epidemiology of molecularly defined brain tumor types. The findings illustrate the success of developing a dedicated, integrated diagnosis variable that provides critical molecular information about brain tumors related to accurate diagnosis.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Funda Meric-Bernstam et al.

Summary: Futibatinib, a selective FGFR1-4 inhibitor, showed clinical activity in various solid tumors, particularly in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. It also demonstrated efficacy in patients who developed resistance to prior FGFR inhibitors. These findings provide a basis for further clinical trials and highlight the importance of genomic profiling in identifying patients who may benefit from targeted therapy.

CANCER DISCOVERY (2022)

Add to Collection

Review Oncology

Ependymoma: Evaluation and Management Updates

Roberta Ruda et al.

Summary: This review summarizes the molecular genetics and management advances in ependymomas of children and adults. Spinal ependymomas have a lower occurrence rate and better prognosis compared to intracranial ependymomas. The new WHO classification has categorized ependymomas into different subgroups based on histomolecular characteristics, which have different outcomes. The extent of resection has a major impact on the treatment efficacy, and conformal radiotherapy and chemotherapy are recommended as treatments. Standard treatments are currently the mainstay, but the discovery of new druggable pathways holds promise for future therapeutic options.

CURRENT ONCOLOGY REPORTS (2022)

Add to Collection

Article Oncology

Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma

Vidhya M. Ravi et al.

Summary: This study utilizes spatially resolved transcriptomics, metabolomics, and proteomics to characterize glioblastomas and uncover their spatial organization and adaptive mechanisms to inflammatory and metabolic stimuli. The integration of metabolic imaging and imaging mass cytometry reveals the interdependence between tumor and host in a locoregional manner, leading to spatially exclusive adaptive transcriptional programs. The findings confirm the importance of environmental stress in shaping glioblastoma subclones and their transcriptional programs.

CANCER CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Glioblastoma hijacks neuronal mechanisms for brain invasion

Varun Venkataramani et al.

Summary: A subpopulation of glioblastoma cells lacking connections with other tumor cells and astrocytes but receiving synaptic input from neurons drives whole-brain colonization. These cells resemble neuronal and neural-progenitor-like states and invade the brain using mechanisms similar to neuronal migration. Neuronal activity induces calcium signals, leading to the formation of tumor microtubes and increased invasion speed. This study reveals how neuronal mechanisms govern glioblastoma cell invasion and explains the close interlink between tumor dissemination and cellular heterogeneity.

CELL (2022)

Add to Collection

Article Oncology

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

Andrew B. Lassman et al.

Summary: This study reports the final long-term survival results of the European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 trials, comparing radiotherapy with and without PCV chemotherapy for anaplastic oligodendroglial tumors. The results show similar long-term survival rates even without tumor recurrence.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

EANO-EURACAN-SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

Roberta Ruda et al.

Summary: The new WHO 2021 Classification of CNS Tumors includes various rare tumor entities that are more commonly found in children, adolescents, and young adults. The Task Force has reviewed the evidence for diagnostic and therapeutic interventions, drawing recommendations primarily for adult patients. Tumor diagnosis is primarily done using histological techniques, but molecular workup is important for unresolved cases. MRI findings are non-specific but can be characteristic for certain tumors. Gross total resection is the most important treatment for prolonging survival and achieving seizure control. Radiotherapy should be considered for certain grades of tumors. Reoperation and radiotherapy may be useful for recurrent tumors. Targeted therapies can be used in selected patients based on molecular alterations. Sequencing is advocated for diagnostic clarification and guiding targeted therapies.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas

Marco Rossi et al.

Summary: The study found that supratotal resection is strongly associated with good oncological outcomes in molecularly defined lower-grade gliomas, regardless of molecular subtypes and grading.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation

Elia Manfrini et al.

Summary: The clinical implementation of qMRI methods across Europe shows significant variability, with different countries demonstrating varying levels of usage. While most neuroradiologists endorse the use of qMRI for improved diagnostic accuracy, there is a need for better technology, more communication, and assistance with result interpretation/generation. Awareness and dissemination of guidelines such as QIBA and EIBALL could help promote broader implementation of qMRI techniques.

EUROPEAN RADIOLOGY (2021)

Add to Collection

Article Oncology

Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up

P. Roth et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Quinn T. Ostrom et al.

Summary: The report from CBTRUS provides the most up-to-date population-based data on primary brain tumors in the United States, including incidence rates, mortality rates, and survival rates for both malignant and non-malignant tumors.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Chinese Glioma Genome Atlas (CGGA) : A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients

Zheng Zhao et al.

Summary: The Chinese Glioma Genome Atlas (CGGA) is a user-friendly data portal for the storage and interactive exploration of cross-omics data related to gliomas. It provides researchers with rapid and convenient access to high-quality functional genomic data resources for biological studies and clinical applications.

GENOMICS PROTEOMICS & BIOINFORMATICS (2021)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Clinical applications of artificial intelligence and radiomics in neuro-oncology imaging

Ahmed Abdel Khalek Abdel Razek et al.

Summary: This article provides a comprehensive overview of the application of artificial intelligence and radiomics in the field of neuro-oncology, primarily focusing on diagnosis, grading, treatment response prediction, and prognosis of brain tumors.

INSIGHTS INTO IMAGING (2021)

Add to Collection

Article Oncology

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C. Mircea S. Tesileanu et al.

Summary: This study examined the molecular and clinical factors related to outcomes in IDH1/2-mutant anaplastic astrocytoma patients. Both epigenetic classifiers and independent prognostic factors were identified for poor prognosis. These results will help improve the current WHO criteria for glioma classification.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Clinical Neurology

Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis

Meng Cui et al.

Summary: PET has moderate diagnostic accuracy in differentiating between true glioma progression (TPR) and post treatment-related change (PTRC). Amino acid PET shows high sensitivity while FDG-PET demonstrates high specificity. Combining commonly used FET-PET and FDG-PET may provide more accurate results, especially for low-grade gliomas.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Subgroup and subtype-specific outcomes in adult medulloblastoma

Hallie Coltin et al.

Summary: Medulloblastoma in adults can be classified into WNT, SHH, Group 3, and Group 4 subgroups, with SHH tumors being diagnosed at an older age. The 5-year progression-free survival varies among different subtypes, but clinical variables do not show a significant association with subtype-specific PFS.

ACTA NEUROPATHOLOGICA (2021)

Add to Collection

Review Clinical Neurology

MRI biomarkers in neuro-oncology

Marion Smits

Summary: The central role of MRI in neuro-oncology is vital for diagnosis and monitoring, treatment decision-making, and assessing treatment response. While currently primarily used qualitatively, advances in quantitative imaging techniques show promising clinical potential for neuro-oncology.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Editorial Material Oncology

Hypermutated recurrences: Identifying the clinical relevance

Marjolein Geurts et al.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Oncology

Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23

Peter Hau et al.

Summary: This study focuses on medulloblastoma in post-pubertal patients, discussing its rarity, treatment options, and clinical trial design. By comparing treatment with SMO inhibitors for SHH subgroup patients, the aim is to improve treatment efficacy, reduce toxicity, and provide guidance for future clinical trials.

CANCERS (2021)

Add to Collection

Review Clinical Neurology

An update on the central nervous system manifestations of Li-Fraumeni syndrome

Brent A. Orr et al.

ACTA NEUROPATHOLOGICA (2020)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study

Kaspar Draaisma et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin van den Bent et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Clinical Neurology

An update on the CNS manifestations of brain tumor polyposis syndromes

Byungjin Kim et al.

ACTA NEUROPATHOLOGICA (2020)

Add to Collection

Article Oncology

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Clinical Neurology

Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14

M. Y. Deng et al.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2020)

Add to Collection

Article Oncology

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Annette M. Molinaro et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Clinical Neurology

Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features

Emily A. Sloan et al.

ACTA NEUROPATHOLOGICA (2020)

Add to Collection

Article Oncology

Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas

Scott Ryall et al.

CANCER CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Florian Klemm et al.

CELL (2020)

Add to Collection

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Mechanisms and therapeutic implications of hypermutation in gliomas

Mehdi Touat et al.

NATURE (2020)

Add to Collection

Article Oncology

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balana et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Clinical Neurology

cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors

David W. Ellison et al.

BRAIN PATHOLOGY (2020)

Add to Collection

Review Oncology

How did lomustine become standard of care in recurrent glioblastoma?

Michael Weller et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Article Oncology

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma

Ingo K. Mellinghoff et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Clinical Neurology

Effect of Comorbid Depression on Surgical Outcomes After Craniotomy for Malignant Brain Tumors: A Nationwide Readmission Database Analysis

Kavelin Rumalla et al.

WORLD NEUROSURGERY (2020)

Add to Collection

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy A systematic review and meta-analysis

Longlong Wang et al.

MEDICINE (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis

Chong Hyun Suh et al.

EUROPEAN RADIOLOGY (2019)

Add to Collection

Article Endocrinology & Metabolism

Hypothalamic-pituitary axis irradiation dose thresholds for the development of hypopituitarism in adult-onset gliomas

Nikolaos Kyriakakis et al.

CLINICAL ENDOCRINOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger et al.

LANCET (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy et al.

NATURE MEDICINE (2019)

Add to Collection

Review Oncology

Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review

Motomasa Furuse et al.

RADIATION ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

Erica Hlavin Bell et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study

Philipp Kickingereder et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

Cyril Neftel et al.

CELL (2019)

Add to Collection

Article Clinical Neurology

MYCN amplification drives an aggressive form of spinal ependymoma

David R. Ghasemi et al.

ACTA NEUROPATHOLOGICA (2019)

Add to Collection

Article Multidisciplinary Sciences

Glutamatergic synaptic input to glioma cells drives brain tumour progression

Varun Venkataramani et al.

NATURE (2019)

Add to Collection

Article Oncology

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

Andrew S. Chi et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Longitudinal molecular trajectories of diffuse glioma in adults

Floris P. Barthel et al.

NATURE (2019)

Add to Collection

Editorial Material Oncology

On high-risk, low-grade glioma: What distinguishes high from low?

Marjolein Geurts et al.

CANCER (2019)

Add to Collection

Review Oncology

Fluorescence guided surgery by 5-ALA and intraoperative MRI in high grade glioma: a systematic review

Jan Coburger et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

Add to Collection

Article Oncology

Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide

Michael Dworkin et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

Add to Collection

Article Oncology

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Genetics & Heredity

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert M. Samstein et al.

NATURE GENETICS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Zhan Yao et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma

Enrico Franceschi et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Design Characteristics of Studies Reporting the Performance of Artificial Intelligence Algorithms for Diagnostic Analysis of Medical Images: Results from Recently Published Papers

Dong Wook Kim et al.

KOREAN JOURNAL OF RADIOLOGY (2019)

Add to Collection

Article Oncology

EANO guidelines for the diagnosis and treatment of ependymal tumors

Roberta Ruda et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Article Oncology

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

Maarten M. J. Wijnenga et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Article Clinical Neurology

Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations

Annekathrin Reinhardt et al.

ACTA NEUROPATHOLOGICA (2018)

Add to Collection

Review Oncology

Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions

Silvia Scoccianti et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice

S. C. Thust et al.

EUROPEAN RADIOLOGY (2018)

Add to Collection

Article Oncology

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment

Hendrik Witt et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Review Oncology

Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review

Margriet IJzerman-Korevaar et al.

JOURNAL OF NEURO-ONCOLOGY (2018)

Add to Collection

Article Oncology

MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis

Praneil Patel et al.

NEURO-ONCOLOGY (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis

Bart R. J. van Dijken et al.

EUROPEAN RADIOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial

Roger Stupp et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Article Oncology

Does early resection of presumed low-grade glioma improve survival? A clinical perspective

Maarten M. J. Wijnenga et al.

JOURNAL OF NEURO-ONCOLOGY (2017)

Add to Collection

Article Oncology

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry

Birthe Krogh Rasmussen et al.

JOURNAL OF NEURO-ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent et al.

LANCET (2017)

Add to Collection

Review Oncology

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma

Andrea Pace et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Genetics & Heredity

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Beatrice S. Melin et al.

NATURE GENETICS (2017)

Add to Collection

Article Oncology

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial

Renske Gahrmann et al.

NEURO-ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

James R. Perry et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

Andrew S. Venteicher et al.

SCIENCE (2017)

Add to Collection

Letter Neurosciences

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Rouzbeh Banan et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)

Add to Collection

Article Clinical Neurology

Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis

Anna F. Delgado et al.

AMERICAN JOURNAL OF NEURORADIOLOGY (2017)

Add to Collection

Article Oncology

Surgical resection versus watchful waiting in low-grade gliomas

A. S. Jakola et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Clinical Neurology

Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging

Z. Xing et al.

AMERICAN JOURNAL OF NEURORADIOLOGY (2017)

Add to Collection

Article Oncology

The Microenvironmental Landscape of Brain Tumors

Daniela F. Quail et al.

CANCER CELL (2017)

Add to Collection

Article Oncology

Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study

Johan A. F. Koekkoek et al.

SUPPORTIVE CARE IN CANCER (2016)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Imaging of oligodendroglioma

Marion Smits

BRITISH JOURNAL OF RADIOLOGY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

Michele Ceccarelli et al.

CELL (2016)

Add to Collection

Article Oncology

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

Vijay Ramaswamy et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

Tomohiro Kawaguchi et al.

JOURNAL OF NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

Nathalie L. Albert et al.

NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial

Bogdana Suchorska et al.

NEURO-ONCOLOGY (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Radiomics: Images Are More than Pictures, They Are Data

Robert J. Gillies et al.

RADIOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis

Ming-Tsung Chuang et al.

PLOS ONE (2016)

Add to Collection

Article Clinical Neurology

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

David E. Reuss et al.

ACTA NEUROPATHOLOGICA (2015)

Add to Collection

Article Oncology

Spatiotemporal Evolution of the Primary Glioblastoma Genome

Jinkuk Kim et al.

CANCER CELL (2015)

Add to Collection

Article Oncology

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Kristian W. Pajtler et al.

CANCER CELL (2015)

Add to Collection

Article Oncology

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Dual-time-point O-(2-[18F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas

Philipp Lohmann et al.

EUROPEAN RADIOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

Hoon Kim et al.

GENOME RESEARCH (2015)

Add to Collection

Article Oncology

Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes

Weiliang Chen et al.

MEDICAL ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

Daniel J. Brat et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Correlation of 18F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool

William Omar Contreras Lopez et al.

ONCOTARGETS AND THERAPY (2015)

Add to Collection

Article Oncology

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics

Walter Taal et al.

JOURNAL OF NEURO-ONCOLOGY (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma

Nathalie L. Jansen et al.

JOURNAL OF NUCLEAR MEDICINE (2015)

Add to Collection

Article Oncology

Health-related quality of life and cognitive functioning in longterm anaplastic oligodendroglioma and oligoastrocytoma survivors

Esther J. J. Habets et al.

JOURNAL OF NEURO-ONCOLOGY (2014)

Add to Collection

Article Oncology

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Mark R. Gilbert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Letter Medicine, General & Internal

Bevacizumab for Newly Diagnosed Glioblastoma Reply

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Review Clinical Neurology

Epilepsy in the end of life phase of brain tumor patients: a systematic review

Johan A. F. Koekkoek et al.

NEURO-ONCOLOGY PRACTICE (2014)

Add to Collection

Article Medicine, General & Internal

Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Clinical Neurology

Differentiation of Primary Central Nervous System Lymphomas and Glioblastomas: Comparisons of Diagnostic Performance of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging without and with Contrast-Leakage Correction

C. H. Toh et al.

AMERICAN JOURNAL OF NEURORADIOLOGY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

The Somatic Genomic Landscape of Glioblastoma

Cameron W. Brennan et al.

CELL (2013)

Add to Collection

Article Oncology

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Mark R. Gilbert et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma

Marion Rapp et al.

JOURNAL OF NUCLEAR MEDICINE (2013)

Add to Collection

Article Oncology

[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma

Markus Hutterer et al.

NEURO-ONCOLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

Andrea Sottoriva et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Oncology

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Roger Stupp et al.

EUROPEAN JOURNAL OF CANCER (2012)

Add to Collection

Article Oncology

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Annika Malmstrom et al.

LANCET ONCOLOGY (2012)

Add to Collection

Article Oncology

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick et al.

LANCET ONCOLOGY (2012)

Add to Collection

Article Oncology

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The Rescue Approach

James R. Perry et al.

CANCER (2008)

Add to Collection

Article Health Care Sciences & Services

The end-of-life hospital setting in patients with glioblastoma

Stefan Oberndorfer et al.

JOURNAL OF PALLIATIVE MEDICINE (2008)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

FET PET for the evaluation of untreated gliomas:: correlation of FET uptake and uptake kinetics with tumour grading

Gabriele Poepperl et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis

Shuichi Higano et al.

RADIOLOGY (2006)

Add to Collection

Article Oncology

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

C Hunter et al.

CANCER RESEARCH (2006)

Add to Collection

Article Medicine, General & Internal

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults:: the EORTC 22845 randomised trial

MJ van den Bent et al.

LANCET (2005)

Add to Collection

Article Oncology

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma

LE Abrey et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Medicine, General & Internal

MGMT gene silencing and benefit from temozolomide in glioblastoma

ME Hegi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Medicine, General & Internal

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

R Stupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Clinical Neurology

O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas

D Pauleit et al.

BRAIN (2005)

Add to Collection

Article Oncology

Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy - A phase II study

AA Brandes et al.

CANCER (2004)

Add to Collection

Article Clinical Neurology

The spectrum of long-term epilepsy-associated tumors:: Long-term seizure and tumor outcome and neurosurgical aspects

C Luyken et al.

EPILEPSIA (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.